NCT00406796View on ClinicalTrials.gov

Lucentis for Central Retinal Vein Occlusion (CRVO)

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

September 30, 2008

Study Completion Date

October 31, 2010

Conditions
Central Retinal Vein Occlusion
Interventions
DRUG

Ranibizumab

0.3mg and 0.5mg dose of Ranibizumab 0.05ml administered intravitreally

Trial Locations (4)

93030

California Retina Consultants, Oxnard

93103

California Retina Consultants, Santa Barbara

93309

California Retina Consultants, Bakersfield

93454

California Retina Consultants, Santa Maria

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

California Retina Consultants

OTHER